Mizukami I F, Faulkner N E, Gyetko M R, Sitrin R G, Todd R F
Department of Internal Medicine, University of Michigan Medical School, Ann Arbor, USA.
Blood. 1995 Jul 1;86(1):203-11.
The receptor for urokinase plasminogen activator (uPA-R, CD87) is a glycosylphosphatidylinositol (GPI)-anchored 50 to 65 kD glycoprotein that, by regulating membrane-associated plasmin activity, may facilitate the invasion of inflammatory and malignant cells. Certain other GPI-anchored glycoproteins are shed from the cell membrane and exist as soluble products in vitro and in vivo. To determine if uPA-R undergoes a similar phenomenon, we have developed a sensitive enzyme-linked immunoabsorbent assay (ELISA) (using a rabbit antiserum as both capture and detection reagents) to measure the quantity of soluble uPA-R (suPA-R) in tissue culture supernatants and biologic fluids. Using this ELISA, we have detected suPA-R in the culture supernatants of U-937 cells and human monocytes stimulated in vitro by certain soluble inflammatory mediators (Sitrin et al, Blood 84:1268, 1994; Mizukami et al., Clin Res 42:115A, 1994). To determine if suPA-R exists in vivo, we have screened the plasma of 20 normal volunteers (mean +/- SD, 3 +/- 3 ng/mL; median, 2 ng/mL; range, 1 to 11 ng/mL [serum values slightly higher]); the plasma of 13 ICU patients with clinical sepsis syndrome (mean +/- SD, 30 +/- 11 ng/mL; median, 11 ng/mL; range, 4 to 221 ng/mL); and the extravascular fluids (pleural, pericardial, and peritoneal) of 84 individuals with presumed inflammatory or malignant conditions (mean +/- SD, 21 +/- 39 ng/mL; median, 10 ng/mL; range, 2 to 253 ng/mL). Among the latter specimens, most were inflammatory exudates (only six were malignant by positive cytology) with the highest quantities of suPA-R associated with neutrophilic exudates. The solubility of suPA-R contained within these fluids was confirmed by reanalysis after ultracentrifugation to remove particulate material. When tested in a uPA ligand capture ELISA, representative specimens of extravascular body fluids and sepsis plasma contained suPA-R capable of binding uPA ligand (generally representing a small fraction of the immunoreactive material). We conclude from these data that suPA-R is immunologically detectable in vitro and in vivo with high concentrations of receptor found under conditions of inflammatory stimulation. The possibility of suPA-R's biologic activity is suggested by its partial retention of ligand binding capacity.
尿激酶型纤溶酶原激活剂受体(uPA - R,CD87)是一种糖基磷脂酰肌醇(GPI)锚定的50至65kD糖蛋白,通过调节膜相关纤溶酶活性,可能促进炎症细胞和恶性细胞的侵袭。某些其他GPI锚定糖蛋白可从细胞膜上脱落,在体外和体内以可溶性产物形式存在。为了确定uPA - R是否也会发生类似现象,我们开发了一种灵敏的酶联免疫吸附测定法(ELISA)(使用兔抗血清作为捕获和检测试剂)来测量组织培养上清液和生物体液中可溶性uPA - R(suPA - R)的量。使用这种ELISA,我们在体外受某些可溶性炎症介质刺激的U - 937细胞和人单核细胞的培养上清液中检测到了suPA - R(西特林等人,《血液》84:1268,1994;水kami等人,《临床研究》42:115A,1994)。为了确定suPA - R在体内是否存在,我们检测了20名正常志愿者的血浆(均值±标准差,3±3 ng/mL;中位数,2 ng/mL;范围,1至11 ng/mL [血清值略高]);13名患有临床脓毒症综合征的重症监护病房患者的血浆(均值±标准差,30±11 ng/mL;中位数,11 ng/mL;范围,4至221 ng/mL);以及84名疑似患有炎症或恶性疾病个体的血管外液(胸腔、心包和腹腔)(均值±标准差,21±39 ng/mL;中位数,10 ng/mL;范围,2至253 ng/mL)。在后者的标本中,大多数是炎症渗出液(只有6例经阳性细胞学检查为恶性),其中中性粒细胞渗出液中suPA - R的含量最高。通过超速离心去除颗粒物质后重新分析,证实了这些液体中所含suPA - R的溶解性。在uPA配体捕获ELISA中进行检测时,血管外体液和脓毒症血浆的代表性标本中含有能够结合uPA配体的suPA - R(通常占免疫反应性物质的一小部分)。从这些数据我们得出结论,suPA - R在体外和体内均可通过免疫检测到,并且在炎症刺激条件下可发现高浓度的受体。suPA - R部分保留配体结合能力提示了其具有生物活性的可能性。